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INTRODUCTION
The intestinal microbiota plays beneficial roles in many physi-
ological processes of the host. It extracts energy and nutrition 
from food, protects against enteropathogens, and supports de-
velopment and maintenance of the host immune system.1-3 The 
biodiversity of the intestinal microbiota among individuals im-
plies that it sustains a homeostatic equilibrium state against a 
decrease in its composition and function.4,5 The particular in-
terrelationship between the intestinal microbiota and the host 
is a product of long-term coexistence and evolution.5-7 Dysbio-
sis, a disruption of microbial composition by various stresses, 
has been implicated in inflammatory bowel disease (IBD), co-
lon cancer, obesity, asthma, and other diseases.1,8,9 The first step 
in treatment of these diseases is to understand the symbiotic 
relationship between the intestinal microbiota and its host. 
Here, we review and outline studies that have discovered how 
antibiotics change microbial composition, resultant physical 
and chemical changes in the body, and how such changes be-
come a trigger for disease. Finally, we discuss recent progress 
toward approaches aimed at restoring a disturbed ecosystem.
SYMBIOSIS AND DYSBIOSIS
Vertebrates host a dense microbial community of bacteria, vi-
ruses, and fungi, namely the microbiota, in organs containing 
mucous membranes, such as the oral cavity and intestines. In 
healthy individuals, Proteobacteria, Bacteroidetes, and Archae-
bacteria are considered the major bacterial taxa.10 Residing in 
the intestines, these diverse microorganisms develop elabo-
rate ecological networks through interactions with other bac-
teria to obtain nutrients required for their colonization and pro-
liferation.3,4,11-13 Host-microbial and microbial-microbial 
interactions establish an equibrilium state of microbial com-
position in the intestinal tract.6,10,14 The complete intestinal mi-
crobiota maintains intestinal symbiosis by suppressing inva-
sion of microorganisms from the outside and regulating the 
excessive proliferation of microorganisms that are present in 
the intestines in small numbers. When the intestinal microbial 
communities collapse or become unbalanced due to a variety 
of causes, such as antibiotics, chemical toxic substances, 
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pathogen infections, and drastic changes in dietary habits, the 
immune responses of the host act abnormally leading to 
IBDs.6,8,15 In particular, excessive dosing of antibiotics elicits the 
loss of naturally occurring intestinal microbiota. Such loss in-
creases the numbers of yeasts, such as Candida albicans, and 
bacteria, such as Proteus, Staphylococcus, and Clostridium dif-
ficile (C. difficile), that normally exist at low numbers, leading 
to depression of digestive functions or the occurrence of intes-
tine-related diseases.8,9,16,17 It is understood that external stim-
uli initially induce disturbances in the intestinal environment 
that result in one of four states−resistance, resilience, redun-
dancy, or dysbiosis−depending on whether the disturbance is 
overcome by the intestinal microbial ecosystem.4,12,14,18-20 When 
the intestinal microbiota responds appropriately to any fluctua-
tions and is recovered to its original state before being stressed 
by environmental perturbations, the intestinal environmental 
state is considered to be resistance.7 However, in cases where 
the stress is very powerful, alterations in the community at the 
level of genera or species and loss of functions occur, and the 
intestinal environment begins to change in the following three 
directions: If the effect is insignificant, the intestinal ecosystem 
enters a resilience state with a microbial community similar to 
the original one through reshaping toward the initial state. In 
the state of redundancy, growth of bacteria different from those 
in the initial state increases such that the diversity of the bacte-
ria increases, although the genes do not undergo functional 
changes. In this case, proteins and metabolites similar to those 
in the initial state, in terms of function, are produced.12,18,21 Re-
sistance, resilience, and redundancy are attributes that appear 
when the intestinal microbiota is strong and shows functional 
recovery.14,15,18 In contrast, dysbiosis refers to a state where ir-
reversible changes occur in the intestinal microbiota with vari-
ations and functional damage at the level of genes or proteins, 
eventually leading to disturbances of responses and the im-
mune system in intestinal epithelial cells, together with chang-
es in intestinal metabolites.
ANTIBIOTICS ALTER THE BALANCE OF 
COMMUNITY AND FUNCTION OF 
INTESTINAL MICROBIOTA 
Antibiotics can be a very powerful factor causing imbalance of 
the intestinal microbiota.22-24 In 1954, Bohnhoff, et al. noticed 
that mice that were given streptomycin were easily infected by 
Salmonella enterica serovar Enteritidis and introduced the 
concept that intestinal microbiota could suppress the growth 
of bacteria that invade mice from the outside through coloni-
zation resistance.25 Direct interaction of intestinal microbiota 
with bacteria and competition for intestinal nutrients are di-
rect methods of inhibiting the intestinal colonization of 
pathogens. However, dosing with antibiotics reduces the diver-
sity and abundance of intestinal microbiota, leading to a re-
duction in the competitive exclusion ability.26-28 Indirectly, this 
destroys the community structure, thereby disturbing the in-
teractions among microbial species and the complementary 
systems of nutrient metabolic pathways, resulting in widespread 
fluctuations in the intestinal environment. These changes are 
not fully reversed, even after several months of discontinua-
tion of dosing.16,22 Eventually, the antibiotic-induced dysbiosis 
of the intestinal microbiota affects the development and regu-
lation of the immune system and increases the risk of intestine-
related diseases, such as IBDs and infectious diseases, in ad-
dition to diverse immunity-related disorders, such as allergic 
or atopic skin diseases and type 1 diabetes.16,28,29 In an experi-
ment where mice were treated with antibiotics at sub-thera-
peutic concentrations, changes in the composition of intestinal 
microbiota were associated with changes in total body weight, 
body fat content, bone density, production of short-chain fatty 
acids (SCFAs), and hepatic fatty acid metabolism. To under-
stand the effects of antibiotics on the homeostasis of the im-
mune system, we first need to understand how antibiotics ex-
tensively change the intestinal microbial ecosystem. Antibiotics 
are generally administered to kill specific microorganisms; 
however, since most antibiotics have a wide range of effects, 
they also affect related microorganisms. These effects are im-
printed in the intestinal environment for several months after 
discontinuation of the dosing.19,23,30,31 The effects of the antibi-
otics on the taxonomic composition of intestinal microbiota 
vary among individuals, and symptoms, such as reduction of 
the diversity of bacteria, a decrease in homology, and relative ex-
cessive increases of certain species, are restored or persist. 
Other symptoms may also occur, depending on differences in 
characteristics among individuals.
Studies on the effect of exposure to antibiotics immediately 
after birth show that the abundance and diversity of intestinal 
microbiota change regardless of the kind of antibiotic.32,33 The 
intestinal microbiota of preterm infants born before 33 weeks 
is about 10 times smaller than that of infants born at term. In 
addition, exposure to diverse antibiotics immediately after 
birth also leads to marked differences in the initial formation of 
microbial communities. In particular, the abundance and di-
versity of the intestinal microbiota decreases rapidly with ex-
posure to meropenem, cefotaxime, and ticarcillin-clavulanate. 
Unlike other antibiotics, administration of vancomycin and 
gentamicin does not change the diversity very much, but incr-
eases in the expression of genes related to resistance to these 
antibiotics are observed. Upregulation of such genes shows a 
close relationship with increases in certain microorganisms. 
In particular, ticarcillin-clavulanate and ampicillin are associ-
ated with a marked increase in Klebsiella pneumoniae, together 
with an increase in gene expression related to resistance to the 
antibiotics.34 
Anaerobic bacteria account for a large proportion of the in-
testinal microbiota and play an important role in the develop-
ment of intestinal immunity.15,26,32,33,35 These organisms pro-
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duce volatile fatty acids, such as butyrate, which activate im-
mune cells to help maintain a healthy gut. Clindamycin, a br-
oad-spectrum antibiotic against anaerobic bacteria, is released 
from bile after administration and accumulates at high con-
centrations in the feces, affecting the composition of the intes-
tinal microbiota for a long time, even after discontinuation of 
dosing.22 Clindamycin is known to have the greatest effect on 
the function of intestinal microbiota that shows resistance to 
the pathogenic bacteria C. difficile. Studies of the effects of clar-
ithromycin, metronidazole, and omeprazole on the composi-
tion of the pharyngeal and fecal bacterial taxa show that these 
antibiotics may affect 30% or more of the microbiota compo-
sition, and although the microbiota may partially recover, the 
effects can persist for at least 4 years after exposure.33 In addi-
tion, analysis of the changes in microbiota between before and 
after treatment of patients with fluoroquinolone and β-lactam 
antibiotics for 1 week showed that the 16S rRNA copy number 
did not change or increased, while changes in the composition 
of microbiota and a reduction in the diversity were observed. 
In particular, an increase in the ratio of Bacteroidetes to Fir-
micutetes was observed, and the distribution of the bacterial 
taxa tended to be simplified.26 
Even ciprofloxacin, which exhibits relatively low activity ag-
ainst anaerobic bacteria, can have a profound effect on the 
composition of intestinal microbiota.36,37 Ciprofloxacin was pre-
scribed for 5 days to patients who had not taken the antibiotic 
previously and changes in the intestinal microbiota between 
60 days before dosing and after dosing and between after dos-
ing and 6 months after discontinuation of dosing were ana-
lyzed. The results showed that the diversity of bacterial taxa 
decreased by approximately one-third, and the taxonomic ab-
undance, diversity, and uniformity of the intestinal microbiota 
decreased.36,38 The results of another study indicated that the 
diversity of the bacterial taxa had already begun to decrease 
in the early stages of exposure to the antibiotic, and when dif-
ferences in responses among individuals and the degree and 
time of recovery of the microbiota were measured, universal 
decreases in Ruminococcaceae were observed, in addition to 
the rapid destruction of bacterial diversity. Although some 
compositional changes persisted, even after 6 months had pass-
ed, most of the compositions showed a tendency to recover 
almost completely by 1 month after dosing. These differences 
were shown to be attributable to the diversity of intestinal mi-
crobiota in the early stage, indicating that the diversity of the 
bacterial taxa of intestinal microbiota plays an important role in 
the subsequent recovery of diversity to the redundancy state.5,37 
In addition, re-exposure to the same amount of ciprofloxacin 
6 months later showed similar effects on the structure of intes-
tinal microbiota, although there was a tendency for less effi-
cient recovery.36
PROLIFERATION OF INTESTINAL 
INFECTIOUS BACTERIA
Antibiotics trigger the proliferation of intestinal pathogenic 
bacteria22 due to the ability of infectious bacteria to effectively 
exploit the disorder that arises when the intestinal microbiota 
has collapsed.10,39 Although there are still many questions about 
the causes of increased bacterial infections in the intestines 
after antibiotic treatment, the most interesting facts revealed 
thus far are described below (Fig. 1).  
Inflammatory responses of hosts
In the intestinal environment, obligatory anaerobic bacteria 
such as Bacteroidia and Clostridia lack genes related to aero-
bic respiration and grow through the fermentation of amino 
acids or polysaccharides (Fig. 1A). Imbalance of the intestinal 
microbiota induces intestinal inflammatory responses, and 
the most important environmental change in this regard is the 
increase in reactive nitrogen species (RNS) and reactive oxygen 
species (ROS). In the case of patients suffering from IBD, ex-
pression of inducible nitric oxide synthase in the intestinal ep-
ithelium increases and nitric oxide (NO−) concentrations in the 
lumen of the colon increases. NO− reacts with superoxide rad-
icals (O2−) to give peroxynitrite (ONOO−), thereby producing ni-
trate (NO3−), or oxidizes organic sulfides and tertiary amines 
into S-oxides and N-oxides, respectively. Unlike obligatory an-
aerobic bacteria, Enterobacteriaceae are capable of anaerobic 
respiration using nitrate, S-oxides, and N-oxides as the final 
electron transport receptors.40 ROS and RNS produced by the 
host’s immune system can be utilized by facultative anaerobic 
bacteria such as Escherichia coli (E. coli) and aerobic bacte-
ria.41,42 E. coli is present in small numbers in healthy intestines, 
but its levels tend to increase significantly in streptomycin-treat-
ed mice (Fig. 1B). An E. coli mutant lacking moaA, a gene nec-
essary for the biosynthesis of the molybdenum cofactor that is 
absolutely necessary for the activity of nitrate reductases, S-
oxide reductases, and N-oxide reductases, tends to show a re-
duction in intestinal proliferation in mice with inflammation 
induced by dextran sulfate sodium.42 Salmonella also undergo 
aerobic respiration using the ROS produced by neutrophils 
and tetrathionate (S4O62-), an electron transfer compound pro-
duced in the oxidation pathway of hydrogen sulphide (H2S) 
produced by microorganisms (Fig. 1B).42 In a study of the 
pathogenesis of Vibrio cholerae under the oxidative stress in-
duced by various antibiotics, overgrowth of Enterobacteriace-
ae and Enterococci was observed after administration of 
streptomycin.43 This study showed that changes in the com-
munity of intestinal microbiota caused by the antibiotic lead 
to increases in ROS in the intestinal environment. Atypical E. 
coli harboring extra catalase (katE) are adapted to this envi-
ronment and excessively proliferate resulting in a temporary 
decrease in the ROS concentration, and cholera bacteria can 
effectively use such conditions (Fig. 1E).
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Intestinal nutrients
Microorganisms produce and consume products through dif-
ferent metabolic pathways, and the ecosystem therefore con-
sists of highly sophisticated networks.44,45 The Archaebacteriae 
Methanobrevibacter smithii and Bacteroides thethaiotaomi-
cron can be more effectively established in sterile rats together 
than singly due to cooperation in polysaccharide metabolism 
through the pathway that converts fructan to acetate and the 
resultant formate.46 In addition, results indicating that Bifido-
bacterium adolescentis, which degrades macromolecular car-
bohydrates, is capable of providing the substrates lactate and 
acetate to bacteria that produce butyrate in the intestines dem-
onstrate the ability of bacteria to use each other to overcome 
conditions of insufficient metabolic pathways.47 
Antibiotics have been reported to alter the intestinal micro-
biota involved in carbohydrate metabolism, thereby increas-
ing the intestinal concentrations of carbohydrates essential for 
the proliferation of infectious bacteria.48 Most intestinal resident 
bacteria and pathogenic bacteria can utilize intestinal sialic 
acid (Neu5Ac) as a nutrient (Fig. 1C). Bacteroides thetatiotao-
micron (B. thetatiotaomicron), one of the representative com-
mensal bacteria, possesses a sialidase enzyme capable of de-
Fig. 1. Pathogens exploit the antibiotic-induced inflammatory conditions. Pathogens use sugars and inorganic compounds generated by the intestinal 
microbiota as carbon or energy sources and perform anaerobic respiration in the inflammatory conditions caused by antibiotics. (A) When the distri-
bution of intestinal microorganisms is in a stable state, the invasion of pathogenic bacteria is suppressed by antimicrobial substances produced from 
intestinal bacteria and host cells and the inflammation is suitably controlled. (B) In an inflammatory condition, the colonization of E. coli and Salmo-
nella expands through anaerobic respiration using ROS and RNS, which are released by DUOX2 and iNOS in epithelial cells. Hydrogen sulfide de-
rived from sulfate-reducing bacteria such as Desulfovibrio spp. is converted to thiosulfate during cellular respiration in colonic epithelial cells. ROS 
generated by neutrophils convert the thiosulfate into tetrathionate that can be used as an electron acceptor. During this process, the generated tetra-
thionate boosts the growth of S. Typhimurium through tetrathionate respiration that converts tetrathionate to thiosulfate. E. coli reduces nitrate to ni-
trite through nitrate respiration. (C) Bacteroides thetaiotaomicron decomposes mucosal glycoconjugates to produce sialic acid. EHEC and Salmonel-
la can use the sialic acid as a carbon source. Inflammatory conditions lead to release of fucose from host glycan and the liberated fucose is 
subsequently consumed by pathogens. As an example, EHEC are known to regulate the expression of virulence genes by sensing the fucose. (D) C. 
difficile, C. rodentium, and EHEC utilize succinate, which is produced by other intestinal microorganisms. SCFAs excreted during polysaccharide me-
tabolism by aerobic bacteria and butyrate, propionate, and acetate are predominantly present in the intestinal environment. A commensal bacterium, 
Bacteroides spp., mainly distributes succinate, which is subsequently consumed by secondary fermentative microbes in a steady state and therefore 
rarely accumulates in the intestinal environment. However, succinate is not consumed under antibiotic treatment or inflammatory conditions, eventu-
ally leading to its accumulation in the intestinal lumen. Succinate promotes gluconeogenesis of EHEC. In addition, the colonization and proliferation of 
C. rodentium are enhanced, especially with expression of virulence genes of the LEE. C. difficile can couple succinate metabolism and convert it to 
butyrate with the fermentation of carbohydrates, thereby enhancing its colonization and virulence. (E) Antibiotics can trigger the growth of Entero-
bacteriaceae. ROS at high concentrations result in an expansion of E. coli harboring an extra catalase that are genetically generated through chro-
mosomal modification and eventually favor intestinal colonization of Vibrio cholerae, a strain that is highly sensitive strain to ROS, by reducing the 
ROS that are excessively generated in inflammatory conditions. E. coli, Escherichia coli ; ROS, reactive oxygen species; RNS, reactive nitrogen spe-
cies; iNOS, inducible nitric oxide synthase; EHEC, Enterohemorrhagic Escherichia coli; C. difficile, Clostridium difficile; C. rodentium, Citrobacter ro-
dentium; SCFAs, short-chain fatty acids; LEE, locus of enterocyte effacement.
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grading glycoconjugates present in the mucosa in order to 
produce sialic acid but the metabolic pathway that consumes 
it is incomplete.49 In contrast, Salmonella enterica serovar Ty-
phimurium (S. Typhimurium hereafter) and C. difficile have a 
nan operon, which is necessary to use sialic acid, but do not 
have sialidase, which is required to produce sialic acid from 
the intestinal mucosa. When B. thetatiotaomicron was trans-
ferred to germ-free mice and the degree of sialic acid metabo-
lism by S. Typhimurium and C. difficile in these mice was com-
pared with that in untreated mice, increases in the expression 
of nanE (a gene in the sialic acid degradation pathway) and 
the fuc1 operon (fucose metabolizing gene cluster) were ob-
served in S. Typhimurium proliferating in B. thetatiotaomicron 
mice. In the case of C. difficile, increases in the expression of 
nanA and nanE genes were observed. In addition, when nor-
mal mice were treated with streptomycin relatively more sialic 
acid was produced and increases in the expression of genes re-
lated to sialic acid metabolism were identified in the group treat-
ed with the antibiotic.49 Another study reported that C. difficile 
is capable of proliferating in the intestine using the succinate-
butyrate metabolic pathway (Fig. 1D). In the presence of B. thet-
atiotaomicron, the pathway by which C. difficile metabolizes 
succinate, a product of fermentation by B. thetatiotaomicron, 
into butyrate is further induced.50 In environments with excess 
polysaccharide, B. thetatiotaomicron produces a high concen-
tration of succinate and C. difficile produces butyrate. In addi-
tion, the amount of succinate present in the intestines of mice 
with normal bacterial flora increased following antibiotic treat-
ment, and mutant strains deficient in the ability to use succi-
nate due to loss of the succinate transporter showed decreased 
intestinal proliferation.50 In fact, B. thetatiotaomicron is a nor-
mal intestinal bacterial flora and a beneficial bacterium with 
the ability to metabolize diverse carbohydrates. Therefore, the 
production of succinate also occurs under the condition of nor-
mal bacterial flora.51 However, in this study, levels of the SCFAs 
acetate and butyrate decreased, while that of succinate in-
creased, in intestines where diarrhea was induced by treatment 
with antibiotics or polyethylene glycol, indicating that the in-
crease in succinate due to changes in intestinal gluconeogene-
sis caused by antibiotics can be one of the various causes that 
promote the proliferation of C. difficile. The use of succinate is 
also observed in Citrobacter rodentium (C. rodentium) (Fig. 1D). 
C. rodentium is known to initiate expression of the pathogenic 
factor genes ler, espA, eae, nleAr, and stx2, which are the locus 
of the enterocyte effacement genes essential for intestinal in-
fections, by recognizing succinate and regulating the tran-
scription factor Cra.52 
Respiratory electron transport system components
Intestinal inflammatory responses help S. Typhimurium spread 
to the lumen of the large intestine, and migration to the colon 
facilitates feces-oral cavity transfer to other highly susceptible 
hosts.25,53,54 S. typhimurium, which induces salmonellosis in 
humans, has been reported to be amplified in mice treated 
with vancomycin and streptomycin.16 In particular, excessive 
use of antibiotics during post-operative convalescence may 
cause recurrence of bacterial infections and pathological symp-
toms. Known pathogenic factors for non-typhoid Salmonella, 
such as S. typhimurium, include the invasion-associated type 
III secretion system (T3SS-1) necessary for the pathogen to 
enter the intestinal epithelial cells, and the second type III se-
cretion system (T3SS-2) necessary for survival of the pathogen 
in the tissues. The increase in proliferation of S. Typhimurium 
in the intestines is attributed to increases in respiratory elec-
tron transport components generated during the host’s in-
flammatory responses (Fig. 1B). For instance, S. Typhimurium 
can form nitrate, a substrate for anaerobic respiration, using 
RNS, one of the outcomes of inflammation.55 Other examples 
are explained by the use of SCFAs (Fig. 2A). SCFAs such as bu-
tyrate, acetate, and propionate are produced by the anaerobic 
bacteria present in the large intestine and are used for barrier 
functions such as IL-8 secretion and mucus production by in-
testinal epithelial cells, the tight junction between intestinal 
cells, and the activation of intestinal cells.44,56,57 They are also used 
as an energy source for intestinal cells. In addition, butyrate 
plays a role in regulating hypoxia-inducible factor (HIF), a tran-
scription factor that regulates the barrier function, mucus pro-
duction, and defends against pathogens of intestinal epithelial 
cells.45,57 The epithelium of the large intestine is relatively hy-
poxic because it is located between the intestinal lumen with 
low oxygen partial pressure and the lamina propria with high 
oxygen concentration. SCFAs promote O2 consumption of hu-
man intestinal cells to maintain the intestinal environment an-
aerobically and stabilize HIF-1α, a subunit of HIF. After treat-
ment with antibiotics, staining with the O2- sensitive dye pi-
monidazole was lost, and the activity of HIF-1α was decreased. 
In addition, oral administration of butyrate resulted in an in-
crease in HIF-1α concentration and buytrate concentration-
dependent recovery of the barrier effect of intestinal cells.45 
Antibiotic treatment increases oxygen production in the co-
lon epithelial cells, increasing the oxygen content in the intes-
tinal lumen. A decrease in Clostridia, a producer of butyrate, 
is expected to increase the oxidation reactions of the intestinal 
cells and promote the diffusion of oxygen into the intestinal lu-
men (Fig. 2). Oxygen is the only respiratory electron transport 
receptor with greater oxidation-reduction potential than ni-
trate, and is more effectively used by aerobic or facultative an-
aerobic microorganisms. The oxygen partial pressure, which 
is about 100 mm Hg in the basal layer, becomes 20−40 mm Hg 
in the mucus layer and reaches almost 0 mm Hg in the lumen, 
leading to hypoxia.58 Therefore, changes in the intestinal oxy-
gen partial pressure caused by antibiotic treatment are the 
first obstacle to the survival of intestinal microbiota and can 
be a very important factor in the induction of infectious disease. 
Colonic cells oxidize butyrate to form CO2, leading to a hypoxic 
(<7.6 mm Hg or <1% O2) state. However, in the case of neona-
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Fig. 2. Effects of antibiotics on the hypoxia barrier of intestinal epithelial cells. (A) In normal conditions, oxygen tension decreases steadily from the in-
testinal submucosal layer to the lumen. Although the partial pressure of oxygen is approximately 100 mm Hg in the basal layer, it is almost 0 mm Hg in 
the lumen. Under antibiotic treatment or inflammatory conditions, Clostridia produce butyrate and colonic epithelial cells convert the butyrate to car-
bon dioxide, leading to maintenance of hypoxia in the lumen. (B) When butyrate is lacking in the intestine, the cells utilize glucose for cellular respira-
tion and the lactate that is released during the process increases oxygenation within the lumen. S. Typhimurium can proliferate using cytochrome bd-
II oxidase encoded in cyxB, which is highly expressed at low oxygen concentrations.
A B
O2
(mm Hg)
tal mice, since butyrate, which is a metabolite of intestinal mi-
crobiota, is not present, energy is obtained by producing lac-
tate from glucose. This process increases the oxygenation of 
intestinal cells.45 For respiration using oxygen, Salmonella 
uses cytochrome bd oxidase produced by cydA and cytoch-
rome bd-II oxidase produced by cyxB. Salmonella can prolif-
erate using the cytochrome bd-II oxidase at a low oxygen partial 
pressure (0.8%) (Fig. 2B).54 Moreover, treatment with tributyrin 
rescued the large intestine of streptomycin-treated mice from 
the hypoxia state and increased the butyrate concentration of 
the cecum.
TREATMENT OF ANTIBIOTIC-RELATED 
DISEASES
The most serious gut-associated disease caused by antibiotics 
is pseudomembranous, which is a typical antibiotic-associat-
ed diarrhea caused by an increase in C. difficile. C. difficile in-
fection (CDI) is one of the most common pathogenic infec-
tions, and is particularly prevalent among patients continuously 
taking antibiotics.48,59,60 CDI was first recognized in advanced 
countries such as the United States and European countries 
where many cases are observed. The treatment and recurrence 
of this disease occur repeatedly, and since recurrent cases can-
not be easily treated with general antibiotics, this bacterium is 
classified as a serious disease causative organism.59 Control 
and complete treatment of C. difficile is hard because its spores 
can survive several years, even in alcohol.48 Although there is 
a continuously increasing trend in the number of CDI patients 
in foreign countries the number of cases in South Korea is still 
small, although collective outbreaks are considered possible.
Approaches such as developing antibiotics with a new ac-
tive mechanism, targeting pathogenic factors, or using native 
microorganisms such as probiotics, have been attempted.61,62 
However, such developments or attempts still generate many 
controversies in terms of safety or effectiveness. In the follow-
ing section, representative non-antibiotic treatment methods 
used to treat C. difficile and other gut-associated diseases are 
introduced. 
Fecal microbiota transplantation
Fecal microbiota transplantation (FMT), a method that in-
volves injecting the fecal microorganisms of healthy persons 
who are highly likely to have similar structures of intestinal mi-
crobiota to those of the patient in order to restore normal bac-
terial flora in the intestines, has been shown to be effective in 
diverse clinical trials. Transplantation of the fecal microbiota 
leads to re-establishment of the patients’ intestinal environ-
ment with the composition of the intestinal microbiota of the 
donor, eventually inducing relative control of C. difficile and 
thereby enabling effective treatment.63,64 This method is very 
effective and has been reported to show cure rates in the range 
of 80−100%, according to the number of times of FMT admin-
istration. It is very efficient in that the provision of healthy in-
testinal microbiota enables acquisition of the ability to resist 
the secondary problem of infection with other pathogens such 
as vancomycin-resistant Enterococcus and carbapenem-re-
sistant Enterobacteriaceae.48,64,65 FMT appears to be an impor-
tant alternative to antibiotics that destroy important commen-
sal bacteria and provides colonization resistance, such as niche 
exclusion for pathogens, the production of antimicrobials, 
and activation of the immune system of the mucous layer.64 
Recent studies have attempted to control Salmonella infec-
tions using bacterial flora, the taxa and characteristics of which 
were identified among bacteria isolated from the intestines.62 
The Microbial Ecosystem Therapeutic (MET-1) is an ecologi-
cal system of 33 kinds of microorganisms isolated from hu-
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man feces, consisting of Actinobacteria (mainly Bifidobacteri-
um spp.), Bacteroidetes, Firmicutes, and Proteobacteria. In 
MET-1-treated mice, body weight loss due to S. Typhimurium 
infection was observed, as well as a decrease in serum cyto-
kines, NF-κB nuclear staining, and neutrophil infiltration in 
the cecum. In addition, ZO-1, a tight junction protein, was pre-
served in the cecum, cellular localization of claudin-1 de-
creased, and S. Typhimurium translocation to the spleen de-
creased. However, there was no change in the colony forming 
units of Salmonella in the intestine. Therefore, MET-1 was th-
ought to regulate systemic infections through maintenance of the 
tight junction to control access to the systemic circulation.62 
Despite many attempts and positive results, questions still 
remain about the safety of FMT. The interactions between pa-
thogenic bacteria and microorganisms are not simple and re-
lated information is still insufficient. In addition, industrial use 
of FMT is increasing, and the use of FMT by patients who have 
not been definitely diagnosed with CDI may cause other prob-
lems, and there is the possibility of the existence of other patho-
gens in the donor’s intestinal microbiota. Therefore, the use of 
FMT requires strict criteria regarding the optimized composition 
of intestinal microbiota, based on the composition and func-
tions of microorganisms that fit the causative disease to be treat-
ed, the age of the recipient, and the stage of disease progres-
sion.63 Obtaining a verified bacterial flora through total examin-
ation of the health condition of the donor, determination of 
whether any genetic disease is latent, and detailed analysis of 
the composition of intestinal microbiota is very important.64 
Probiotics
The focus on probiotics began in 1908 when Metchnikoff re-
ported the relationship between fermented food and longevity, 
explaining that intestinal microbiota develop the mucosal im-
mune system and can prevent the invasion of infectious bac-
teria. Thereafter, diverse bacterial taxa were tested under vari-
ous experimental conditions to determine whether probiotics 
could treat a variety of gut-associated diseases such as Crohn’s 
disease and ulcerative colitis, Irritable Bowel Syndrome, CDI, 
infectious diarrhea, and necrotizing enterocolitis.35,61,66,67 The 
idea that probiotics could improve or prevent diarrhea began 
with the notion that these gut-associated diseases were 
caused by the collapse of “colonization resistance” due to the 
absence of normal bacterial flora. In many studies, probiotics 
have been used to treat gut-associated diseases through acti-
vation of the immune system, competition for settlement sites 
in the intestinal cells, and the production of bacteriocin. These 
effects vary with the form and causes of diarrhea, such as viral 
diarrhea, antibiotic-related diarrhea, or traveler’s diarrhea.
Probiotics are known to be very effective for the treatment of 
antibiotic-associated diarrhea, with Saccharomyces boulardii 
(S. boulardii), E. coli Nissle 1917, Lactobacillus, and Bifidobac-
terium as the main focus of research.66,68 Positive effects were 
identified under conditions where lactic acid bacteria such as 
Lactobacillus GG (LGG), S. boulardii, E. faecium, Lactobacillus 
acidophilus (L. acidophilus), and Lactobacillus bulgaris were 
taken together with diverse types of antibiotics.35 When healthy 
adults were instructed to take erythromycin and LGG, a reduc-
tion in the duration of diarrhea symptoms from 8 days to 2 days 
was observed, and the incidence of related symptoms such as 
abdominal pain was reduced from 39% to 23%. In a pediatric 
study conducted with approximately 200 children who were 
administered antibiotics, prescription of LGG reduced the in-
cidence of diarrhea from 26% to 8% and reduced the period of 
diarrhea from 5.88 days to 4.7 days.67 In addition, L. plantarum 
299v administered together with oral antibiotics alleviated the 
symptoms of diseases that occurred when the use of antibiotics 
was discontinued, and L. rhamnosus prevented diarrhea caused 
by antibiotic treatment.68 S. boulardii is able to degrade C. diffi-
cile toxin A and toxin B by releasing a 54 kDa protease. In a study 
conducted with 138 hospital patients in which patients who 
were randomly prescribed with the probiotic strain were com-
pared with placebo patients, only 2.9% of those who took the 
probiotics were found to be C. difficile toxin-positive, compared 
with 7.25% of placebo patients.61 When all fecal samples were 
examined, only 46% of the group that took probiotics showed C. 
difficile toxin-positive reactions compared with 78% of the pla-
cebo group. In addition, the efficacy of probiotics as adjuvant 
therapeutic agents has also been demonstrated. In a study 
conducted with 124 adult Clostridium difficile-associated dis-
ease patients, approximately 60% of patients prescribed with S. 
boulardii together with antibiotics showed relief of infection 
symptoms. In addition, S. boulardii has also shown relative ef-
fects for the prevention of secondary diseases in patients at risk 
of recurrence of CDI,61,67 although this is controversial.
The results of studies conducted thus far indicate that the 
mechanisms through which probiotics can treat diseases are 
quite diverse, and information on which mechanisms individ-
ual probiotics induce has not been fully verified. These mech-
anisms vary with the types of bacterial taxa used as probiotics 
and the kind of experimental disease, and the known effects 
mainly include maintenance of interactions between the host 
and microorganisms, removal of bacteria, mucus secretion 
from goblet cells, control of the epithelial barrier function of 
the intestinal cells, production of anti-bacterial factors such as 
lactic acid, hydrogen peroxide, and bacteriocin, and activa-
tion of the acquired immune system of the host.20,35,67,68 How-
ever, the different mechanisms used to produce beneficial ef-
fects make the selection of probiotics difficult. Essentially, to 
verify the effects it is necessary to identify whether the probi-
otics would survive, as well as the surface proteins and bacte-
riocin produced. In addition, in order to use probiotics for di-
verse diseases, both the disease and the mechanisms of the 
probiotics should be accurately delineated. Careful selection 
of fully understood and proven probiotics may provide an al-
ternative therapy to improve health and replace antibiotics for 
primary therapeutic purposes.
11
Mi Young Yoon and Sang Sun Yoon
https://doi.org/10.3349/ymj.2018.59.1.4
CONCLUSION
Antibiotic-associated diarrhea occurring in patients who take 
antibiotics emphasizes the importance of a balanced intesti-
nal microbiota. The effects of antibiotics on intestinal micro-
biota are in fact clues to understanding which molecular sub-
stances or mechanisms each infectious bacterium can ef-
fectively utilize in the changed environment in order to grow 
and cause disease in the host environment. Recent studies have 
provided information on how antibiotics can alter the intesti-
nal environment, how harmful bacteria and beneficial bacte-
ria react, and how pathogenic bacteria use these environments. 
Pathogens exploit the sugars, radicals, and oxygen occurring 
as a result of disruption of intestinal microbiota and the host 
inflammatory response. Application of FMT and probiotics for 
eradication of gastrointestinal diseases and enteropathogens 
exhibits the potential to restore the degraded ecosystem and 
protection against colonization and proliferation of entero-
pathogens. This new research has given us a greater under-
standing and new directions when considering future ap-
proaches to treat antibiotic-related infectious diseases.
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